AbbVie (ABBV) Profit After Tax (2012 - 2026)

AbbVie (ABBV) has reported Profit After Tax for 15 consecutive years, with $697.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 45.93% year-over-year to $697.0 million; the TTM figure through Mar 2026 stood at $3.6 billion (down 13.35% YoY), while the FY2025 annual figure was $4.2 billion, down 1.22% from the prior year.
• Profit After Tax fell to $697.0 million in Q1 2026 per ABBV's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Profit After Tax topped out at $4.5 billion in Q1 2022 and bottomed at -$22.0 million in Q4 2024.
• Historically, Profit After Tax has averaged $1.5 billion across 5 years, with a median of $1.4 billion in 2024.
• Annual changes were most pronounced in 2024 — Profit After Tax sank 102.68% — and 2025, when it soared 8354.55%.
• AbbVie's Profit After Tax stood at $2.5 billion in 2022, then sank by 66.76% to $822.0 million in 2023, then plunged by 102.68% to -$22.0 million in 2024, then jumped by 8354.55% to $1.8 billion in 2025, then slumped by 61.62% to $697.0 million in 2026.
• Business Quant data shows ABBV's Profit After Tax at $697.0 million in Q1 2026, $1.8 billion in Q4 2025, and $186.0 million in Q3 2025.